Mike Doustdar

Do things get better from here?

What I can tell you is that the first nine months of the year, 15% sales growth and 10% profit growth is not so bad at all compared to our peers.

But...

I think when you look at it, quarter by quarter, there has been a headwind and bringing the quarterly growth rates lower.

If you project our numbers for the full year, actually, you see that quarter four should be in negative territory.

So that you see mathematically.

So this isn't the low point.

The low point is still to come, but things get better from there?

There's for sure a headwind against us.

Having said this...

We are in a business of marathons and not sprints.

So there is huge amount of unmet need with many patients still not on our medications or not on any medications.

And I look incredibly forward, of course, as we go forward, taking over this new job, making sure that we expand the market and get to those people.

You've been in the job for 91 days.

You haven't let the grass grow under your feet.

You're already talking about cost cuts.

You will talk about it in a minute.

You've launched a big M&A deal.

Is this the new Novo?

Is this a more dynamic, aggressive Novo Nordisk under your tenure?